Skip to main content
HR 2855 117th Congress House Health Health care costs and insurance Health care coverage and access Health care quality Health programs administration and funding Medicare Performance measurement Prescription drugs

Star Rating for Biosimilars Act

Introduced: April 26, 2021 Introduced by: Tonko, Paul Democratic · New York See on congress.gov
Sign in to write a letter Sign in to watch
This bill died when the 117th Congress ended
It never became law before the 117th Congress (2021–2022) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 5 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Apr 27, 2021
Referred to the Subcommittee on Health.
Apr 26, 2021
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Apr 26, 2021
Introduced in House
Apr 26, 2021
Referred to the Subcommittee on Social Security.
Apr 26, 2021
Referred to the Subcommittee on Health.
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

Star Rating for Biosimilars Act

This bill requires the Centers for Medicare & Medicaid Services (CMS) to establish quality measures regarding biosimilar biological products under the five-star performance rating system for Medicare Advantage plans. The measures must assess the level of access that plans provide to covered biosimilars, including with respect to formularies, cost-sharing, and utilization management.

The CMS must also incorporate such measures into similar rating systems for plans under the Medicare prescription drug benefit.

What's happening now April 27, 2021

Referred to the Subcommittee on Health.

 Related & companion bills 2
  • HR 5260 Related bill Reduced Costs and Continued Cures Act
  • HR 5237 Related bill Reduced Costs and Continued Cures Act of 2021
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 5
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 2855: Star Rating for Biosimilars Act. 117th Congress. Open America. https://openamerica.io/bill/117-HR-2855/
MLA
"H.R. 2855: Star Rating for Biosimilars Act." 117th Congress, 2026, Open America, https://openamerica.io/bill/117-HR-2855/.
Bluebook (legal)
H.R. 2855, 117th Cong. (2026), https://openamerica.io/bill/117-HR-2855/.
Markdown link
[H.R. 2855: Star Rating for Biosimilars Act](https://openamerica.io/bill/117-HR-2855/)
Report a problem